Sangamo Therapeutics (SGMOQ) Other financing activities (2013 - 2025)

Sangamo Therapeutics' Other financing activities history runs 10 years deep, the most recent figure standing at $52.0 million for Q4 2025.

• On a quarterly basis, Other financing activities rose 17832.76% year-over-year to $52.0 million in Q4 2025; TTM through Dec 2025 was $52.2 million, a 17894.83% increase from a year earlier, with the FY2025 full-year figure at $52.2 million, up 17894.83% from the prior year.
• Other financing activities climbed to $52.0 million in Q4 2025 per SGMOQ's latest filing, from $1000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $52.0 million in Q4 2025 and bottomed at -$22.4 million in Q2 2024.
• The 4-year median for Other financing activities is $234500.0 (2024), against an average of $4.2 million.
• Across the five-year window, Other financing activities tumbled 99.15% in 2022 and soared 17832.76% in 2025, its largest moves.
• Year by year, Other financing activities stood at $1.1 million in 2021, then tumbled by 96.81% to $34000.0 in 2022, then soared by 752.94% to $290000.0 in 2024, then surged by 17832.76% to $52.0 million in 2025.
• Per Business Quant, the three latest SGMOQ Other financing activities figures stand at $52.0 million (Q4 2025), $1000.0 (Q3 2025), and $179000.0 (Q2 2025).